Pancrelipase
Creon, Pancreaze, Pertzye, Viokace, Zenpep (pancrelipase) is an enzyme pharmaceutical. Pancrelipase was first approved as Cotazym on 1996-12-09. It is used to treat exocrine pancreatic insufficiency in the USA.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
digestive system diseases | D004066 |
Trade Name
FDA
EMA
Creon, Pancreaze, Pertzye, Viokace, Zenpep (discontinued: Cotazym)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Pancrelipase
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Creon | pancrelipase | AbbVie | N-20725 RX | 2009-04-30 | 5 products |
Pertzye | pancrelipase | Digestive Care | N-22175 RX | 2012-05-17 | 4 products |
Pancreaze | pancrelipase | Vivus | N-22523 RX | 2010-04-12 | 6 products |
Viokace | pancrelipase | Viokace | N-22542 RX | 2012-03-01 | 2 products |
Zenpep | pancrelipase | Zenpep | N-22210 RX | 2009-08-27 | 7 products |
Show 1 discontinued
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | C85.9 | 4 | 5 | 1 | — | — | 9 | |
Leukemia | D007938 | C95 | 3 | 3 | 2 | — | — | 8 | |
Mucositis | D052016 | EFO_1001898 | 2 | 1 | 4 | — | — | 6 | |
Stomatitis | D013280 | EFO_1001904 | K12.1 | 2 | 1 | 2 | — | — | 5 |
Head and neck neoplasms | D006258 | 2 | 2 | 3 | — | — | 5 | ||
Neoplasms | D009369 | C80 | — | 1 | 2 | — | — | 3 | |
Colonic neoplasms | D003110 | C18 | — | 1 | 1 | — | — | 1 | |
Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
Squamous cell neoplasms | D018307 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | D46 | 2 | 4 | — | — | 1 | 6 | |
Myeloid leukemia acute | D015470 | C92.0 | 1 | 2 | — | — | 1 | 4 | |
Graft vs host disease | D006086 | D89.81 | 2 | 3 | — | — | 1 | 4 | |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | 1 | — | — | 1 | 3 | |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | — | — | 1 | 3 | |
Hodgkin disease | D006689 | C81 | 1 | 1 | — | — | 1 | 2 | |
X-linked combined immunodeficiency diseases | D053632 | EFO_1001451 | 2 | 2 | — | — | — | 2 | |
Plasma cell leukemia | D007952 | C90.1 | 1 | 1 | — | — | — | 1 | |
Hematologic neoplasms | D019337 | — | 1 | — | — | — | 1 | ||
Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Primary myelofibrosis | D055728 | D47.4 | — | — | — | — | 1 | 1 | |
B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | — | — | — | 1 | 1 | |
Myelomonocytic leukemia chronic | D015477 | C93.1 | — | — | — | — | 1 | 1 | |
Leukemia myeloid chronic atypical bcr-abl negative | D054438 | C92.2 | — | — | — | — | 1 | 1 | |
B-cell lymphoma marginal zone | D018442 | C88.4 | — | — | — | — | 1 | 1 | |
Follicular lymphoma | D008224 | C82 | — | — | — | — | 1 | 1 | |
Mantle-cell lymphoma | D020522 | C83.1 | — | — | — | — | 1 | 1 | |
Myeloid leukemia chronic-phase | D015466 | — | — | — | — | 1 | 1 | ||
Large b-cell lymphoma diffuse | D016403 | C83.3 | — | — | — | — | 1 | 1 | |
Myeloid leukemia accelerated phase | D015465 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | PANCRELIPASE |
INN | — |
Description | Pancreatic enzymes, also known as pancreases or pancrelipase and pancreatin, are commercial mixtures of amylase, lipase, and protease. They are used to treat malabsorption syndrome due to certain pancreatic problems. These pancreatic problems may be due to cystic fibrosis, surgical removal of the pancreas, long term pancreatitis, pancreatic cancer, or MODY 5, among others. The preparation is taken by mouth.
|
Classification | Enzyme |
Drug class | enzymes |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108074 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00085 |
UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Creon - Viatris
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Creon - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zenpep - Allergan
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zenpep - Warner Chilcott
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Pancreaze - Vivus
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 785 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
464 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more